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        Herpesvirus pathogenesis is closely linked to host 
immune status. The majority of herpesvirus-
infected individuals never experience clinical 
symptoms, but infection among the immuno-
compromised is a risk factor for numerous com-
plications (  1  ). MHV68 is a     2 herpesvirus, 
closely related to the human pathogens EBV and 
Kaposi  ’  s sarcoma  –  associated herpesvirus (  2, 3  ). 
Like human herpesviruses, the vast majority of 
MHV68-infected immunocompetent mice do 
not develop disease; however, chronic infection 
of IFN    R      /      mice is a notable exception (  4  –  6  ). 
IFN     directly inhibits viral replication and/or 
reactivation from latency in specifi  c cell types, 
i.e., macrophages but not B cells (  7, 8  ). In the 
absence of an IFN     response in vivo, persistent 
MHV68 replication emerges several weeks after 
infection and promotes a lethal infl  ammatory 
disorder consisting of lymphocytic infi  ltrates in 
multiple organs and fi  brotic changes in the spleen, 
lymph nodes, and lung (  6, 9  ). The resulting pul-
monary disease is studied as a model for human 
idiopathic pulmonary fi   brosis (IPF) associated 
with gammaherpesvirus infection (  10  –  12  ), and 
persistent virus replication in the great elastic ar-
teries gives rise to lesions that bear resemblance 
to clinical vasculitides such as Takayasu  ’  s arteritis 
and Kawasaki disease (  13  –  15  ). Although the pre-
cise etiology of organ fi  brosis is unknown, and 
probably wide ranging in both humans and ani-
mals models, three distinct elements are essential 
in the pathogenesis of MHV68-induced fi  brotic 
disease: (a) persistent viral replication; (b) host T 
cells; and (c) a unique viral gene of unknown 
function, designated M1 (  6, 11, 15, 16  ). 
  The M1 gene of MHV68 suppresses reactiva-
tion from latency in immunocompetent C57BL/6 
mice, but the mechanism by which it exerts 
this eff  ect, and the extent of immune system 
involvement, is unknown (  16  ). The M1 gene is 
unique to MHV68 and is encoded within a locus 
of multiple unique open reading frames (ORFs). 
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  Little is known about herpesvirus modulation of T cell activation in latently infected indi-
viduals or the implications of such for chronic immune disorders. Murine gammaherpesvirus 
68 (MHV68) elicits persistent activation of CD8  +   T cells bearing a V    4  +   T cell receptor 
(TCR) by a completely unknown mechanism. We show that a novel MHV68 protein encoded 
by the M1 gene is responsible for V    4  +   CD8  +   T cell stimulation in a manner reminiscent of 
a viral superantigen. During infection, M1 expression induces a V    4  +   effector T cell re-
sponse that resists functional exhaustion and appears to suppress virus reactivation from 
peritoneal cells by means of long-term interferon-     (IFN    ) production. Mice lacking an 
IFN     receptor (IFN    R      /     ) fail to control MHV68 replication, and V    4  +   and CD8  +   T cell 
activation by M1 instead contributes to severe infl  ammation and multiorgan fi  brotic disease. 
Thus, M1 manipulates the host CD8  +   T cell response in a manner that facilitates latent 
infection in an immunocompetent setting, but promotes disease during a dysregulated 
immune response. Identifi  cation of a viral pathogenecity determinant with superantigen-
like activity for CD8  +   T cells broadens the known repertoire of viral immunomodulatory 
molecules, and its function illustrates the delicate balance achieved between persistent 
viruses and the host immune response. 670 MHV68 M1 ANTIGEN INDUCES V   4 +   CD8 +   T CELLS | Evans et al.
are potentially ground-breaking because they identify a se-
creted viral protein that stimulates murine CD8  +   T cells in an 
apparently novel fashion and demonstrate that such activity 
either contributes to immunological control of infection or 
virus-induced disease, depending on the status of the host  ’  s 
immune system. 
    RESULTS   
  MHV68 immunopathology induced by the M1 ORF 
is associated with the presence of V    4  +   CD8  +   T cells 
  We previously demonstrated that IFN    R      /      mice infected 
with an M1-defi  cient virus do not exhibit the mortality or 
fi  brotic changes associated with WT MHV68 infection (  16  ). 
It was independently shown that both CD8  +   and CD4  +   T cells 
were required for splenic fi  brosis during MHV68 infection (  6  ). 
Therefore, we compared the T cell response elicited by WT 
and M1 mutant MHV68 infection in IFN    R      /      mice. 
We extended the initial observation (which used a mutant 
containing a large insertion into the M1 ORF) using a mutant 
virus with a targeted 511-bp deletion (M1    511) spanning the 
5     end of M1 ORF (  16  ). In agreement with previously pub-
lished data (  16  ), the spleens of M1    511-infected mice exhibited 
a normal histological appearance as compared with M1 marker 
rescue (M1.MR) control virus, which promoted extensive 
fi  brotic scarring and decreased cellularity in infected spleens 
by 1 mo after infection (  Fig. 1 A  ).   Beyond the spleen, M1.MR 
virus induced extensive lymphocytic infi  ltrates  throughout 
the lung and liver, whereas M1    511 virus did not produce 
any signs of disease (  Fig. 1 A  ). 
  When the T cell response for each group of mice was ex-
amined at the same time point, the absence of infl  ammatory 
changes in M1    511-infected animals correlated with the ab-
sence of an activated CD8  +   T cell population (CD11a  hi  , 
CD44  +  , and CD62L  lo  ; unpublished data). Surprisingly, the 
lack of activated T cells in M1    511-infected mice could be 
attributed to a total defi  ciency of V    4  +   CD8  +   T cell expansion 
(  Fig. 1 B  ). A direct association between V    4  +   CD8  +   T cell 
activation and disease was suggested by immunohistochemical 
staining of the pulmonary infi  ltrates from M1.MR-infected 
mice, demonstrating that the infl  ammatory lesions contained 
substantial numbers of V    4  +   and CD8  +   T cells (  Fig. 1 C  ). 
Importantly, the titer of persistently replicating virus in the dis-
eased organs of M1.MR-infected mice was comparable to the 
titer in the healthy tissues from M1    511-infected mice (  Fig. 
1 D  ). In agreement with the absence of pulmonary infl  amma-
tion at 28 d after infection, long-term fi  brotic changes were 
not detected in the lungs of M1    511-infected mice as late as 
180 d after infection as compared with those infected with WT 
MHV68 (  Fig. 1 E  ). Thus, the failure of M1    511 to induce 
chronic T cell  –  mediated fi  brosis correlated with the absence of 
V    4  +   CD8  +   T cell activation and corresponding infl  amma-
tion, strongly suggesting that these T cells play a critical role in 
the pathogenesis of fi  brotic disease in IFN    R      /      mice. These 
data also demonstrate that persistent virus replication is insuffi   -
cient to cause fi  brotic disease in the absence of M1 expression 
and the associated V    4  +   CD8  +   T cell response. 
Each ORF is dispensable for in vitro growth, but critical for 
regulating aspects of in vivo infection (  16  –  23  ). Based on the 
capacity of M1 to inhibit reactivation in vivo, it was un-
expected that M1 also promotes fi  brotic disease in IFN    R      /      
mice  —  a T cell  –  mediated process that was previously thought 
to result directly from persistent virus replication (  11, 16  ). 
  Antiviral CD8  +   T cell responses help control both lytic 
and latent MHV68 infection (  24  –  28  ). Eventually, antigen-
specifi  c T cell responses become down-regulated, exhibit 
little evidence of continued activation, and contract in the 
manner typical of memory T cell responses. (  29  –  31  ). A nota-
ble exception to this pattern is the V    4  +   CD8  +   T cell re-
sponse. In the third week after infection, cells bearing a V    4  +   
TCR rapidly proliferate, rise to the level of 30  –  60% of pe-
ripheral CD8  +   T cells in C57BL/6 mice, and remain at ele-
vated levels throughout the course of latency (  32, 33  ). The 
V    4  +   CD8  +   T cell response has been proposed as a mouse 
model for EBV-induced infectious mononucleosis (IM), 
but the degree of similarity between the two phenomena is 
ill-defi  ned (  34, 35  ). A latency-specifi  c stimulus for the V    4  +   
response is suggested because latency-defi  cient MHV68 mu-
tants fail to generate a response during lytic infection and 
because B cells (the major latency reservoir for MHV68) are 
required for V    4  +   CD8  +   T cell expansion (  30, 36  –  38  ). This 
response is not limited to C57BL/6 mice, but occurs to vary-
ing degrees in a wide variety of inbred mice, demonstrating 
preferential expansion among strains expressing the H2  b   
MHC haplotype (  32, 39  ). Superantigen-driven proliferation 
was proposed for this response because it is confi  ned to cells 
expressing a single variable region in the TCR      chain and 
it is not defi  nitively MHC restricted (  32  ). However, V    4  +   
CD8  +   T cell expansion is not broadly polyclonal (based on 
complementarity-determining region  –  3 size analysis and 
V-D-J junctional region diversity) as demonstrated for classi-
cal CD4  +   superantigen responses (  40  ). Numerous lines of ev-
idence have shown that V    4  +   CD8  +   T cell activation does 
not require classical MHC class Ia antigen presentation, in-
cluding studies of mice defi  cient for MHC class Ia molecules 
(H-2K  b    /        ×   H-2D  b    /     ),     2 microglobulin (    2m      /     ), and 
the transporter associated with antigen processing (TAP      /     ) 
(  37, 41  ). These data either implicate a role for     2m-indepen-
dent, nonpolymorphic MHC class Ib molecules or an un-
conventional, MHC-independent mechanism of CD8  +   T 
cell activation. Ultimately, the identity of the V    4  +   CD8  +   
T cell stimulatory ligand and its biological signifi  cance has 
remained elusive. 
  The goal of this study was to investigate a potential im-
munomodulatory function for the MHV68 M1 gene product 
that could explain its role in regulating virus reactivation and 
disease. This fi  rst led to the surprising fi  nding that the M1-
dependent immunopathology observed in MHV68-infected 
IFN    R      /      mice is associated with activation of the enig-
matic V    4  +   CD8  +   T cell population and second to the 
discovery that the M1 antigen of MHV68 is capable of stimu-
lating V    4  +   CD8  +   T cells both in vivo and in vitro in a 
manner consistent with superantigen-like behavior. These data JEM VOL. 205, March 17, 2008 
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sisting of three recombinant viruses harboring translation stop 
codons within each of the M1 neighboring genes (M2, M3, 
and M4), as well as a large-scale deletion mutant (    9473) that 
spans nearly 9.5 kb and encompasses the entire left end of 
the genome, including M1 (  Fig. 2 C  ) (  17  –  19, 22  ).   After in-
fection of immunocompetent C57BL/6 mice with each virus, 
the extent of V    4  +   CD8  +   T cell expansion was assessed at the 
normal peak of this response at 28 d after infection. Only the 
M1    511 virus and the     9473 virus failed to induce V    4  +   
CD8  +   T cell expansion, whereas the extent of V    4  +   CD8  +   T 
cell expansion was comparable among all other viral mutants 
tested (  Fig. 2, A and B  ). Importantly, the M1    511 mutant 
both replicates and establishes latency in vivo at levels com-
parable to WT virus; thus, the failure of the M1 mutant virus 
  The M1 ORF is required for V    4  +   CD8  +   T cell expansion 
  The V    4  +   CD8  +   T cell response is a highly unusual example 
of an antiviral T cell response because of its activation profi  le, 
kinetics, and apparent MHC independence (  32, 33, 37, 39, 
41  ). The hypothesis that V    4  +   CD8  +   T cell activation is the 
result of a viral superantigen was proposed, but a candidate T 
cell ligand has never been identifi  ed (  32  ). Having demon-
strated that loss of M1 ablates this response, we considered 
that M1 might be the putative viral T cell stimulatory ligand. 
To focus on M1 and rule out other viral factors, we set about 
a more rigorous genetic mapping of adjacent mutations in the 
MHV68 genome that might aff  ect V    4  +   T cell activation. In 
addition to the aforementioned M1    511 mutant and control 
virus, a panel of individual viral mutants was compiled con-
    Figure 1.         M1 and the V    4  +   CD8 T cell response are required for virus-induced infl  ammation and fi  brosis in IFN    -unresponsive mice.  
IFN   R    /     mice were infected with 10  3   PFU of the indicated virus intranasally and analyzed at 28 d after infection in A  –  D. (A) Hematoxylin and eosin 
staining of pathological changes in the spleen, liver, and lung. Bars: (spleen and liver) black, 200   μ  m; (spleen and liver) white, 80   μ  m; (lung) black, 400   μ  m; 
(lung) white, 40   μ  m. (B) Representative fl  ow cytometric plots of V   4 +   CD8 +   T cell populations from mice infected with each virus. Numeric values are 
given for the proportion of CD8  +   cells (right quadrants only). (C) Immunohistochemical staining for CD8  +   cells and V   4 +   cells in infl  ammatory lesions of 
the lung from M1.MR-infected animals, as indicated by brown chromogen deposition. Bars, 160   μ  m. (D) Persistent replication of each virus from each 
organ as measured by plaque assay. (E) Masson trichrome staining of lung sections at 180 d after infection from mice infected with 10  5   PFU of WT or 
M1    511 virus. Blue indicates areas of collagen deposition. Bars, 200   μ  m.     672 MHV68 M1 ANTIGEN INDUCES V   4 +   CD8 +   T CELLS | Evans et al.
failure of previous M1-defi  cient viruses to induce V    4  +   CD8  +   
T cell expansion during latency (  Fig. 2, A and B  ). Likewise, 
M1.STOP infection failed to induce spleen, lung, or liver 
infl  ammatory lesions in infected IFN    R      /      mice, as shown 
for M1    511 virus in   Fig. 1   (not depicted). Thus, we con-
cluded that the MHV68 M1 gene product is critical in pro-
moting the expansion and activation of the V    4  +   CD8  +   T 
cell population. 
  Control of virus reactivation is dependent on the M1 ORF 
and V    4  +   CD8  +   T cell expansion 
  Disruption of the M1 ORF results in enhanced reactivation 
from latency in peritoneal exudate cells (PECs) recovered from 
infected C57BL/6 mice, and thus the M1-encoded gene 
product was proposed to act as an inhibitor of virus reactiva-
tion (  16  ). Indeed, both M1.STOP and M1    511 mutants ex-
hibit roughly a 10-fold higher frequency of reactivation from 
PECs at 6 wk after infection as compared with M1.MR and 
WT MHV68, whereas the frequency of infected cells was the 
same for each (  Fig. 3 B  ).   We postulated that the capacity of 
M1 to suppress reactivation resulted from large-scale V    4  +   T cell 
activation and their acquisition of antiviral eff  ector functions. 
to induce V    4  +   CD8  +   T cell expansion was not caused by 
an attenuated viral infection, as has been shown with other 
latency-defi  cient mutants (  21, 30  ). In addition, the absence of 
V    4  +   CD8  +   T cell expansion after M1    511 infection was not 
the result of delayed kinetics of T cell activation because both 
M1    511 and     9473 viruses did not exhibit any evidence of 
V    4  +   T cell expansion at 42 d, 3 mo, and 1 yr after infection, 
whereas WT and M1.MR virus demonstrated the characteristic 
protracted response (  Fig. 2 B  ). Finally, in the absence of a V    4  +   
CD8  +   T cell response during M1    511 infection, no other V     
subset was seen to expand in compensation (  Fig. 2 D  ). 
  Because the region immediately adjacent to the M1 gene 
contains several viral tRNA-like and putative miRNA genes 
(  42  –  44  ), it was possible that the 511-bp deletion spanning the 
5     end of the M1 gene might also impact expression of one 
or more of these genes (  Fig. 1 C  ). Thus, to more defi  nitively 
determine whether the V    4  +   CD8  +   T cell expansion and ac-
tivation maps to the M1 ORF, we engineered a new MHV68 
M1 mutant, M1.STOP, by altering 6 bp at the 5     end of the 
M1 ORF to introduce two translation stop codons and a 
frameshift mutation ( Fig. 2 C ). Notably, infection of C57BL/6 
mice with the M1.STOP mutant virus fully recapitulated the 
    Figure 2.         The M1 ORF is required for V    4  +   CD8  +   T cell expansion.   (A) C57BL/6 mice were infected intranasally with 10  3   PFU of each viral geno-
type as indicated, and the V   4 +   CD8 +   splenocyte population was measured at 28 d after infection. Representative fl  ow plots for fi  ve viral genotypes, as 
well as uninfected mice, are shown. Numeric values are given for the proportion of CD8  +   cells (right hand quadrants) only. (B) Graphical representation of 
the V   4 +   population size elicited by all viral genotypes, as described in part A, at the indicated times after infection. Data are pooled from 1  –  3 indepen-
dent experiments with 3  –  5 mice per group. Error bars denote the SD. (C) Schematic diagram of the     HV68 genome highlighting the 9.5-kb region of in-
terest with the genetic structure of mutants    9473  ( 16 ),  M1   511 (  15  ), M2.STOP (  18  ), M3.STOP (  22  ), and M4.STOP (  17  ) shown in relation. The novel 
mutations that constitute the M1.STOP virus are underlined (fi  ve base pair substitutions yielding back-to-back translational stop codons, followed by a 
single deletion producing a downstream frameshift). Large and small triangles correspond to the eight viral tRNAs and nine viral microRNAs, respectively (  44  ). 
(D) The V     repertoire of CD8  +   splenocytes was examined 28 d after intranasal infection of a C57BL/6 mouse with 10  3   PFU of the indicated virus.     JEM VOL. 205, March 17, 2008 
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  To further investigate the association between M1 con-
trol of virus reactivation and activation of V    4  +   CD8  +   T 
cells, we took advantage of intrinsic genetic diff  erences be-
tween inbred strains of mice. This approach was necessary 
because attempts to eliminate V    4  +   T cells via antibody de-
pletion proved unsuccessful (see Discussion). The extent of 
MHV68-driven V    4  +   CD8  +   T cell expansion varies widely 
between mouse strains in accordance with their MHC hap-
lotype. Specifi  cally, mice bearing an H-2  b   MHC haplotype 
(e.g., C57BL/6) show a greater V    4  +   CD8  +   T cell expansion 
than animals expressing H-2  d   haplotypes (  39  ). Thus, we rea-
soned that the lack of a robust V    4  +   CD8  +   T cell response 
in mice with an H-2  d   haplotype would minimize the capacity 
of M1 to infl  uence reactivation from latency. To test this 
hypothesis, BALB/c mice (H-2  d  ) were infected with M1.
STOP and WT virus, and the impact of M1 on virus reacti-
vation and V    4  +   CD8  +   T cell expansion was examined. WT 
MHV68 infection of BALB/c mice resulted in a modest, 
approximately twofold expansion of the V    4  +   CD8  +   T cell 
population in the first month after infection, which was 
no longer evident by 1 yr after infection (  Fig. 4, A and B  ).   
Notably, this small expansion was also observed with M1.MR 
virus, but not upon infection with the M1    511 mutant 
(  Fig. 4 A  ). Next, BALB/c mice were infected via intraperi-
toneal inoculation and PEC reactivation was examined at 6 wk 
after infection. As predicted, the frequency of reactivation 
from latently infected PECs did not diff  er signifi  cantly between 
M1.STOP and WT virus-infected mice (  Fig. 4 C  ). Thus, 
we concluded that M1 is incapable of infl  uencing virus reacti-
vation in mice that are intrinsically unable to mount a robust 
Notably, neither M1-dependent reactivation nor V    4  +   CD8  +   
T cell expansion was infl  uenced by viral dose (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20071135/DC1). 
To assess whether the control of reactivation and the stimula-
tion of CD8  +   T cells are functionally linked, reactivation of 
M1-null viruses was examined under conditions in which the 
V    4  +   CD8  +   T cell expansion and activation are not appar-
ent. First, reactivation from latency was measured for each 
virus before the expansion of V    4  +   CD8  +   T cells. We con-
fi  rmed that V    4  +   CD8  +   T cell expansion begins 18  –  20 d 
after infection and that the response does not vary by route of 
infection (unpublished data). Mice were examined at 16  –  18 d 
after intraperitoneal inoculation, and the frequencies of reac-
tivating PECs did not signifi  cantly diff  er between M1.STOP, 
M1    511, M1.MR, or WT viruses (  Fig. 3 A  ). Thus, M1-de-
pendent control of reactivation can only be detected after 
the expansion of the V    4  +   CD8  +   T cell population. A model 
for control of reactivation by V    4  +   CD8  +   T cells implies 
that their persistent state of activation should predict long-
term viral control that is dependent on M1. Accordingly, 
the frequency of PECs reactivating virus at 195  –  220 d after 
infection from M1    511-infected mice was   >  10-fold higher 
than observed with the M1.MR-infected mice, whereas 
the frequency of viral genome-positive cells was only slightly 
skewed in favor of the mutant (  Fig. 3 C  ). This relatively 
small increase in viral load cannot account for the greatly ele-
vated reactivation seen with M1    511. Thus, the kinetics of 
V    4  +   CD8  +   T cell expansion correlates well with the time 
course over which M1 represses reactivation from latently 
infected PECs. 
    Figure 3.         M1 function suppresses reactivation from latency in accordance with V    4  +   CD8  +   T cell activation.   C57BL/6 mice were infected by 
intraperitoneal inoculation with 10  2   or  10 6   PFU of each indicated virus, and the extent of reactivation and latency among the PECs was quantifi  ed by lim-
iting dilution analyses. Time points were chosen before, after, and long after the V   4 +   CD8 +   T cell expansion had occurred, at 16  –  18 (A), 42  –  44 (B), and 
195  –  200 d (C) after infection, respectively. The frequency of reactivation was measured by plating live cells in a limiting dilution series onto a MEF indica-
tor monolayer and scoring the frequency of wells positive for cytopathic effect (CPE; top). The relative contribution of preformed infectious virus was 
evaluated in parallel by mechanically disrupting the maximum number of cells and plating the cell lysates in parallel. In each of the experiments, the con-
tribution of preformed virus accounted for   ≤  1% of the CPE produced by plating intact cells (not depicted). The frequency of latently infected, viral 
genome-positive cells was measured by subjecting a limiting dilution series of cells to lysis and proteinase K digestion, followed by highly sensitive nested 
PCR capable of detecting a single copy of the MHV68 genome (bottom). Graphs represent the combined data from three independent experiments with 
4  –  5 animals per group. Error bars denote the SD.     674 MHV68 M1 ANTIGEN INDUCES V   4 +   CD8 +   T CELLS | Evans et al.
V    4  +   CD8  +   T cell response. Collectively, the data showing 
identical kinetics of V    4  +   T cell expansion and M1-dependent 
reactivation in C57BL/6 mice and the absence of an M1-
associated reactivation phenotype in mice that lack robust 
expansion of V    4  +   CD8  +   T cells, argue that the M1-dependent 
control of virus reactivation from latently infected PECs func-
tions through an activated V    4  +   CD8  +   T cell mediator. 
  V    4  +   CD8  +   T cells exhibit an effector memory phenotype 
without signs of functional exhaustion 
  The capacity of V    4  +   CD8  +   T cells to regulate chronic viral 
reactivation implies that these cells are potent antiviral eff  ec-
tor cells. At the peak of the V    4  +   CD8  +   T cell response 
within the spleen, these cells are CD11a (LFA-1)  hi  , CD44  +  , 
CD62L (L-selection)  lo  , and CD127 (IL-7R    )  lo   (  Fig. 5 A  ), al-
though negative for CD25 and CD69 expression as previ-
ously reported (not depicted) (  33  ).   Each feature is maintained 
as late as 6 mo after infection, with the exception of CD127, 
which was up-regulated by this time (  Fig. 4 A   and unpub-
lished data), indicating that the persistence of the V    4  +   CD8  +   
T cell response was analogous to the maintenance of an eff  ec-
tor memory T cell population (  45  ). The V    4  +   population 
also expresses the C-type lectin inhibitory receptor NKG2A, 
which is often found on NK and activated CD8  +   T cells 
(  Fig. 5 A  ) (  46  ). In contrast, V    4  +   CD8  +   T cells did not ex-
press the PD-1 inhibitory receptor at any time between 28 d 
to 6 mo after infection, as is characteristic of activated and/
or chronically exhausted CD8  +   T cells (  Fig. 5 A   and not 
depicted) (  47  ). 
  Ongoing proliferation among the expanded V    4  +   CD8  +   
T cell population appears to be on par with the rate of homeo-
static proliferation among all other CD8  +   T cells in infected 
mice, as determined by in vivo BrdU incorporation over a 1-wk 
course of treatment during the fourth month after infection 
(  Fig. 5 A  ). Cytokine production was measured as an indicator 
of T cell function by ex vivo stimulation with anti-CD3, and 
revealed potent production of both IFN     and TNF-     by 
V    4  +   CD8  +   T cells from 28 d to 6 mo after infection (  Figs. 5, 
A and B, and Fig. 6, C  –  E  ).   Notably, in the absence of M1 ex-
pression and V    4  +   CD8  +   T cell expansion, the proportion of 
CD8  +   T cells capable of eliciting IFN     upon ex vivo stimula-
tion was drastically reduced (  Fig. 5 B   and Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20071135/DC1). 
Thus, the V    4  +   CD8  +   T cell response that resists functional 
exhaustion likely represents a key source of IFN     production 
for the regulation of viral reactivation. 
  M1 encodes a secreted protein capable of stimulating V    4  +   
CD8  +   T cells specifi  cally 
  To assess the possibility that the M1 gene product directly stimu-
lates CD8  +   T cells in a manner analogous to a superantigen, 
    Figure 4.         M1 is incapable of regulating virus reactivation in the 
absence of robust V    4  +   CD8  +   T cell expansion among BALB/c mice. 
  (A) BALB/c mice were infected intranasally with 10  3   PFU of the indicated 
viruses, and the proportion of V   4 +   CD8 +   splenocytes was quantifi  ed at 
the indicated times. Data are pooled from 1  –  2 independent experiments 
with 2  –  4 mice per group. (B) Representative fl  ow plots of the V   4 +   CD8 +  
T cell expansion at 28 d after infection from mice in A. Numeric values are 
given for the proportion of CD8  +   cells (right quadrants) only. (C) Reactiva-
tion from BALB/c PECs was measured by limiting dilution assay from mice 
infected via intraperitoneal inoculation with 10  6   PFU of the indicated viral 
genotype either 42  –  44 or 130  –  132 d earlier. The experimental conditions 
and assays performed here are identical to the experiments performed on 
C57BL/6 mice in   Fig. 3 B  , with the exception of late time point being per-
formed at     4 mo after infection. Red line and symbols, M1.Stop; black 
line and symbols, WT MHV68. Error bars denote the SD.     
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mice 4  –  6 mo after WT MHV68 infection (diagrammed in 
  Fig. 6 B  ). Stimulation of V    4  +   CD8  +   T cells was measured 
using intracellular cytokine (ICC) staining for IFN     produc-
tion. Anti-CD3 antibody was used as a nonspecifi  c TCR 
cross-linking agonist to assess the total capacity for IFN     pro-
duction, and elicited robust cytokine levels from V    4  +   CD8  +   
T cells at all times tested (  Fig. 6 C  ). In cultures containing the 
M1 antigen as a stimulus, a substantial portion (10  –  20%) of 
V    4  +   CD8  +   T cells also produced IFN    , whereas no activa-
tion was elicited by recombinant M3 protein (  Fig. 6 C  ). 
Importantly, M1-mediated T cell stimulation was lost when 
recombinant M1 protein was depleted from the supernatant 
by anti-FLAG immunoprecipitation, indicating that stimula-
tion was specifi  c to the presence of the M1 antigen and not 
a secondary eff  ect of another soluble factor elicited by M1 
expression (  Fig. 7 A  ).   Notably, even in the absence of in vitro 
stimulation, intracellular IFN    could often be detected within 
the V    4  +   CD8  +   T cells from certain infected mice, demon-
strating the likelihood that V    4  +   CD8  +   T cells contribute to 
persistent IFN     production in vivo (  Fig. 6 C  ). In contrast to 
the behavior of the activated V    4  +   CD8  +   T cell population 
recovered from WT MHV68-infected mice, recombinant M1 
antigen was not capable of stimulating IFN     production from 
unexpanded V    4  +   CD8  +   T cells derived from the spleen of 
M1.STOP-infected or naive mice in the ICC assay (Fig. S2). 
The incapacity of M1 to rapidly induce IFN     production 
as originally speculated for the V    4  +   stimulatory ligand (  32  ), 
we generated recombinant protein and tested its capacity to 
activate primary T cells. The putative M1 antigen is predicted 
to be a 47-kD secreted protein, based on the presence of a 
19-aa, N-terminal consensus secretory signal peptide. Notably, 
both the neighboring M3 and M4 genes of MHV68 encode 
secreted proteins, and the low level homology shared be-
tween M1, M3, and M4 ORFs, suggests all three likely arose 
through gene duplication events (  18, 48  ). To determine if 
the M1 antigen is truly a secreted protein with the potential 
to directly interact with V    4  +   CD8  +   T cells, we cloned the 
full-length M1 ORF (with a C-terminal FLAG-epitope tag) 
into a eukaryotic expression vector and expressed M1 by 
transient transfection into Cos-1 cells. As predicted, an     47-kD 
protein was detected in the transfected culture supernatant 
after anti-FLAG immunoprecipitation (  Fig. 6 A  ). Expression 
of a FLAG-tagged version of the MHV68 M3 chemokine-
binding protein served as a positive control for secretory 
transport, whereas a FLAG-tagged MHV68 v-cyclin expression 
vector resulted in protein expression that was detected only 
within the whole-cell lysate (  Fig. 6 A  ). 
  To determine if secreted M1 antigen could directly stim-
ulate V    4  +   CD8  +   T cells in vitro, cell-free supernatants re-
covered from Cos-1 cells transfected with either the M1 
expression vector, or control expression vectors (M3 and 
v-cyclin), were used to stimulate splenocytes recovered from 
    Figure 5.     V    4  +   CD8  +   cells exhibit effector memory T cell characteristics, including potent IFN     production during     HV68 latency.   (A)  CD8 +   T 
cells were examined for multiple markers of T cell activation, proliferation, and effector function after intranasal infection of C57BL/6 mice with 10  3   PFU 
of WT MHV68. All plots are gated on total CD8  +   splenocytes and are representative of multiple samples from independent experiments measured at 28 d 
after infection. Identical analyses were performed as late as 6 mo after infection, and the only signifi  cant change observed was the up-regulation of 
CD127 as shown in the offset panel (gray histogram, 1 mo after infection; black histogram, 6 mo after infection). Representative plots for ICC staining are 
shown from 2.5 mo after infection, at which time splenocytes were cultured in the presence of Brefeldin A and 1   μ  g/ml of soluble anti-CD3 monoclonal 
antibody to elicit cytokine production. BrdU incorporation was measured at 4 mo after infection after a 1-wk course of BrdU administration in the drink-
ing water (0.8 mg/ml) of infected mice. Numeric values are given for the proportion of total CD8  +   cells in each quadrant. (B) ICC staining for IFN     produc-
tion was performed as in A on CD8  +   splenocytes from C57BL/6 mice at 28 d after infection with each indicated viral genotype. Insets show frequency of 
V   4 +   cells from unstimulated controls for each sample. Plots are representative of results for 2  –  3 animals per condition.     676 MHV68 M1 ANTIGEN INDUCES V   4 +   CD8 +   T CELLS | Evans et al.
  To compare the capacity of recombinant M1 to stimulate 
T cells that express V    4  +   TCR alongside other V     elements, 
we examined primary T cells from various times and ana-
tomical sites after infection. First, T cells from mice 12 d after 
from naive V    4  +   T cells ex vivo was not unexpected, as pri-
mary V    4  +   CD8  +   T cell activation during infection requires 
costimulation; even potent CD3 cross-linking was incapable 
of stimulating IFN     among naive T cells in the same assay. 
    Figure 6.     The M1 ORF encodes a 45-kD secreted protein that is capable of stimulating MHV68-induced V    4  +   CD8  +   T cells.   (A) Cos-1 cells 
were transiently transfected with M1 and M3 expression constructs containing C-terminal FLAG epitopes. Whole-cell lysates and cell supernatants were 
immunoprecipitated and detected with anti-FLAG antibody. (B) Schematic diagram of experimental design for T cell stimulation. Supernatants from 
Cos-1  –  transfected cells containing M1 and M3 recombinant protein were compared with complete media with and without 1   μ  g/ml anti-CD3, all supple-
mented with Brefeldin A, for the ability to stimulate primary V   4 +   CD8 +   T cells from infected C57BL/6 mice as determined by ICC staining for IFN    . (C) IFN    
production elicited by the indicated stimuli from CD8  +   splenocytes at 4  –  6 mo after infection. Note that the extent of background IFN     production  among 
unstimulated V   4 +   CD8 +   T cells exhibited mouse-to-mouse variation, but was repeatedly higher then V   4       cells and was most readily detected at a 1:100 
dilution of Brefeldin A (GolgiPlug). Numeric values are given for the proportion of V   4 +   CD8 +   cells (right quadrants) only. (D) IFN     production elicited by 
the indicated stimuli from CD8  +   splenocytes at 12 d and 2 mo after infection. Numeric values for the proportion of V   4 +   cells (right quadrants only) 
are given for the 2-mo time point in larger font, and the total proportion of CD8  +   cells in each quadrant are given for both time points in parentheses. 
(E) IFN     production elicited by the indicated stimuli from CD8  +   PECs at 2 mo after infection. Numeric values are reported as in D. In all panels, plots are 
representative of two or more independent experiments, each containing 2  –  3 mice.     JEM VOL. 205, March 17, 2008 
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infection (lacking an expanded V    4  +   population) were com-
pared in parallel with those from mice 2 mo after infection. 
In side-by-side experiments M1 was devoid of any stimula-
tory activity among the day 12 eff  ector CD8  +   T cells, which 
were capable of responding to anti-CD3 treatment, but pro-
duced signifi  cant up-regulation of IFN     among the V    4  +   
population from latently infected tissues (  Fig. 6 D  ). The same 
pattern was true of cells from the peritoneal compartment. 
Recombinant M1 had no infl  uence on eff  ector CD8  +   T cells 
present during lytic infection (unpublished data), but exhib-
ited robust activity among V    4  +   cells taken at 2 mo after in-
fection (  Fig. 6 E  ). Importantly, peritoneal cells from latently 
infected mice off  ered a comparison of activity among V    4  +   
and V    4        T cells, which are both capable of expressing IFN     
within the same sample, and, as such, demonstrated that 
the infl  uence of M1 was absolutely restricted to the V    4  +   
population (  Fig. 6 E  ). Thus, under these conditions, M1 is 
incapable of stimulating conventional CD8  +   eff  ector T cells 
generated during lytic infection, and shows specifi  city for the 
presence of a V    4  +   TCR upon ex vivo stimulation. The in-
ability of M1 to infl  uence conventional CD8  +   T cell responses 
is further supported by data demonstrating that the peak size 
of an antigen-specifi  c (tetramer-positive) CD8  +   T cell response 
to MHV68 does not signifi  cantly diff  er between infection with 
M1.STOP and WT virus (Fig. S3, available at http://www
.jem.org/cgi/content/full/jem.20071135/DC1). 
  V    4  +   TCR activation by M1 requires a functional protein 
and is independent of professional antigen presentation 
  To assess the requirement for functional M1-mediated protein 
interactions during T cell stimulation, we disrupted native M1 
protein structure via either heat denaturation or enzymatic 
cleavage with thrombin protease (a single predicted thrombin 
recognition site exists midway through the protein). The loss 
of T cell stimulation under either condition suggested M1 
activity was dependent on properly folded, intact recombinant 
protein (  Fig. 7 A  ). Furthermore, it indicated that the stimula-
tory activity is unlikely to result from an M1-derived peptide 
epitope presented in an MHC-dependent context during 
the ICC assay. Such a conclusion was also supported by the 
inability of a proteasome inhibitor (18   μ  M lactacystin) to 
diminish V    4  +   CD8  +   T cell activation mediated by recombi-
nant M1 (unpublished data). From these analyses, we conclude 
that the intact extracellular M1 antigen is required to induce 
V    4-specifi  c T cell stimulation after MHV68 infection, impli-
cating a mechanism for V    -specifi  c TCR engagement in a 
manner similar to known superantigens. 
  Second, we examined the capacity of M1 to stimulate 
MHV68-specifi  c V    4  +   CD8  +   T cell hybridomas. The hy-
bridoma lines respond to MHV68-infected splenocytes even 
in the presence of MHC class I and II blocking antibodies or 
    Figure 7.         V    4  +   TCR stimulation by M1 requires intact protein and 
is independent of professional antigen presentation.   (A)  Histograms 
quantifying the percentage of V   4 +   CD8 +   splenocytes that produce IFN    
under the indicated condition. M1-containing supernatants were modi-
fi  ed in the following manner. Depleted and nondepleted supernatants 
were immunoprecipitated using anti-FLAG- and IgG-conjugated agarose, 
respectively. Thrombin-conjugated agarose was used to protease digest 
recombinant M1, and then enzyme was removed by precipitation and 
inactivated with protease inhibitors. M1 contains a single predicted 
thrombin cleavage domain approximately midway through the primary 
sequence. M1 denaturation was the result of a 10-min incubation at 94  °  C. 
Asterisks indicate signifi  cantly different values for representative columns 
(P   <   0.05). (B) V   4 +   CD8 +   hybridoma (4BH62) was cultured in isolation 
from any other cells for 36 h in the presence of M1- and M3-containing 
supernatants or conditioned supernatants from Cos-1 cells both with and 
without 1   μ  g/ml anti-CD3. Cells were fi  xed, stained with X-gal for LacZ 
expression, and photographed under an inverted microscope. Bars, 80   μ  m. 
(C) ELISA measurements for the concentration of IL-2 in the culture su-
pernatant of each hybridoma line after 36 h stimulation under the indi-
cated conditions, as in part B. The limit of detection is 2 pg/ml. As a 
control, all supernatants were tested and found below the limit of detec-
tion before being used to culture hybridoma lines (not depicted). Error 
bars denote the SD.     
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antigen is necessary for the V    4  +   CD8  +   T cell response to 
occur in vivo and is suffi   cient to induce V    4  +   TCR signaling 
in vitro, conclusively demonstrating that M1 is the viral de-
terminant responsible for this immune reaction. M1 activity 
has several features in common with superantigen-mediated 
T cell activation, including the following: (a) that it occurs 
to varying degrees in multiple MHC backgrounds, (b) is 
independent of professional antigen presentation, and (c) 
is the result of functional protein  –  protein interactions that 
occur specifi  cally with cells bearing a V    4  +   TCR. The con-
sequences of the superantigen-like response determine sev-
eral features of MHV68 infection. Upon activation, V    4  +   
CD8  +   T cells from C57BL/6 mice appear to suppress reac-
tivation from some populations of latently infected cells, 
which correlates with the capacity to express high levels of 
IFN    , a known inhibitor of MHV68 reactivation from macro-
phages (  Fig. 8  ) (  7, 8  ).   Furthermore, in animals unable to regu-
late reactivation via IFN     signaling (IFN    R      /     ), the presence 
of the activated V    4  +   CD8  +   T cell population is associated 
with severe infl  ammation and fi  brotic scarring of multiple 
tissues (  Fig. 8  ). 
  Mechanism of M1 action 
  Identifi  cation of a viral molecule that stimulates CD8  +   T cells 
in a manner reminiscent of a superantigen is a novel discov-
ery in regard to both microbial pathogenesis and T cell re-
ceptor signaling. Superantigens are expressed by other viruses, 
including the mouse mammary tumor virus, mls antigen, and 
Rabies virus nucleocapsid; superantigen activity is implicated 
in EBV, human cytomegalovirus (HCMV), and herpesvirus 
saimiri infection (  49  –  54  ). Like their bacteriological counterparts, 
when infected splenocytes lacking MHC class I expression 
(    2-microglobulin      /     ) are used (  37  ). Each hybridoma line 
(4BH62 and 4BH98) expresses a distinct V    4  +   TCR of dif-
ferent complementarity-determining region  –  3 length and 
contains a     -galactosidase (  LacZ  ) reporter gene regulated by 
the nuclear factor of activated T cells (NF-AT). After 36 h of 
stimulation in the presence of M1-containing supernatant, a 
signifi  cant number of the V    4  +   CD8  +   T cell hybridoma cells 
expressed detectable   LacZ   expression (  Fig. 7 B  ). The number 
of responding cells was on par with the proportion expressing 
  LacZ   after anti-CD3 stimulation, whereas no cells were seen 
to respond to either M3 or mock treatment (  Fig. 7 B  ). Next, 
interleukin-2 (IL-2) secretion was measured under each con-
dition. A non-V    4 CD8  +   T cell hybridoma (LT359) derived 
from a polyoma virus-specifi  c T cell response was used as a 
control for V    -specifi  city. IL-2 production for each V    4  +   
hybridoma was similar, if not greater, after treatment with 
M1 as compared with anti-CD3, whereas background levels 
of IL-2 were undetectable (  Fig. 7 C  ). Notably, the polyoma-
specifi  c V    4        hybridoma demonstrated robust IL-2 production 
in response to anti-CD3 stimulation, but not in response to 
treatment with M1 (  Fig. 7 C  ). Thus, M1 has the capacity to 
induce signaling through multiple TCR clones in a V    4-specifi  c 
manner in the absence of professional antigen-presenting cells 
or any other viral gene product. 
    DISCUSSION   
  The salient features of the V    4  +   CD8  +   T cell response have 
been interpreted as evidence for an unconventional viral 
  superantigen, although no such molecule has previously 
been identifi  ed. Our results demonstrate that the MHV68 M1 
    Figure 8.         Model for M1 antigen  –  mediated control of virus reactivation, and association of M1 antigen with the induction of fi  brotic disease in 
IFN    -unresponsive mice.   (A) Infection of WT C57BL/6 mice elicits a strong V   4 +   CD8 +   T cell response via stimulation by soluble M1. Subsequent virus reacti-
vation events lead to limited V   4 +   CD8 +   T cell activation, IFN     production, and the suppression of virus reactivation from specifi  c latently infected cell popula-
tions (i.e., macrophages). (B) MHV68 infection in IFN   R    /     mice leads to virus reactivation and persistent virus replication. In this scenario, the failure of 
infected cells to respond to IFN    -mediated suppression of virus reactivation leads to hyperactivation of the expanded V   4 +   CD8 +   T cell population, resulting in 
tissue damage by an unknown mechanism (see Discussion). (C) Infection of IFN    -unresponsive mice with M1-null MHV68 fails to elicit expansion or activation 
of V   4 +   CD8 +   T cells, and no tissue damage is observed in this setting, even though there is ongoing virus reactivation and replication, as shown in   Fig. 1 D  .    JEM VOL. 205, March 17, 2008 
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but the in vivo relevance of this activity is not known (  33  ). 
The same study reported V    4  +   T cell depletion has no sig-
nifi  cant impact on viral genome load or reactivation from 
splenocytes, specifi  cally; this is a conclusion that is consistent 
with our own. It should be noted, however, that our attempt to 
perform a similar depletion protocol using the same mono-
clonal antibody (KT4, the only V    4-specifi  c monoclonal 
antibody available to our knowledge) was unsuccessful. Treat-
ment rendered the V    4  +   population undetectable by fl  ow 
cytometry with the same monoclonal antibody, but no change 
in IFN     production was evident in anti-V    4  –  treated versus 
isotype-control  –  treated mice (Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20071135/DC1). These data 
argue that use of the KT4 antibody masks detection with 
the same monoclonal species, but does not eff  ectively deplete 
the V    4  +   CD8  +   T cell population during MHV68 infection. 
Thus, analyses with an M1 mutant virus may be the most 
reliable method for evaluating the functional consequences 
of this T cell response. 
  The capacity of V    4  +   CD8  +   T cells to maintain function-
ality over a period of months, and perhaps years, in spite of 
their continual activation, is in apparent contrast to many an-
tigen-specifi  c T cell responses in other well-known persistent 
viral infections. Chronic lymphocytic choriomeningitis virus, 
hepatitis C virus, and simian and human immunodefi  ciency 
virus infections eventually result in the development of CD8  +   
T cell responses with   “  exhausted  ”   characteristics, including 
poor proliferative potential, limited eff  ector cytokine pro-
duction (i.e., TNF-    ), and reduced cytolytic activity. This 
phenomenon, which is thought to result from chronic expo-
sure to viral antigen, is mediated by the PD-1 surface recep-
tor and contributes to the failure to control viral infection in 
certain cases (  63  ). V    4  +   CD8  +   T cells exhibit the opposite 
profi  le, as they fail to express PD-1 on their surface, maintain 
production of eff  ector cytokines, and exhibit long-term con-
trol of persistent virus reactivation. Such a comparison im-
plies that either a relatively low level of activity is required for 
V    4  +   CD8  +   T cells to control reactivation (i.e., no cytolytic 
activity and limited cytokine production), or that their acti-
vation state is distinct from classical antiviral responses. T cell 
responses to other latent herpesviruses (i.e., EBV and human 
or mouse cytomegalovirus) have been described which do 
not exhibit the hallmarks of exhaustion, but during latency 
the extent of conventional antigen exposure is presumably 
low. The paradox of the V    4  +   CD8  +   T cell response to 
MHV68 is how such a large and activated CD8  +   T cell re-
sponse maintains its size, status, and functional activity. Under-
standing the mechanisms by which M1 induces persistent 
V    4  +   CD8  +   T cell activation may provide insight into TCR 
signaling mechanisms by which more durable and eff  ective T 
cell responses can be generated against chronic viruses. 
  Latency as a requirement for the V    4  +   CD8  +   T cell response 
  Although transcription of the M1 ORF occurs during both 
lytic and latent MHV68 infection, in B cells as well as non-B 
cells, the ability of MHV68 to establish latency in B cells is 
the known viral superantigens mediate bridging interactions 
between MHC class II molecules and V     segments of the 
TCR     -chain on CD4  +   T cells (  55, 56  ). In the case of M1, 
both its specifi  city for CD8  +   cells and its apparent indepen-
dence of MHC class Ia interactions are intriguing features 
that require further elucidation. Importantly, a recent study 
demonstrated that bacterial superantigens are capable of TCR 
stimulation independent of lck-mediated phosphorylation 
events associated with T cell coreceptor engagement (  57  ). 
If conventional superantigen activity functions independent of 
MHC-specifi  city imparted by CD4 and/or CD8 coreceptors, 
a novel superantigen might circumvent classical MHC  –  TCR 
interactions entirely. Indeed, the cumulative data on V    4  +   
CD8  +   T cell activation support this idea. We confi  rmed re-
ports that V    4  +   CD8  +   T cell activation occurs in mice lack-
ing     2m-dependent class I MHC expression (unpublished 
data), and V    4  +   CD8  +   T cell hybridoma activation in the 
presence of MHC class I and II neutralizing antibodies also 
argues against a critical role for antigen-presenting molecules 
in the MHV68-induced response (  37, 41  ). The defective 
V    4  +   CD8  +   T cell response in MHV68-infected MHC class 
II  –  defi  cient mice is likely caused by the absence of CD4  +   T 
cells  —  a known requirement for V    4  +   CD8  +   T cell expan-
sion in vivo (  32, 36, 58  ). Therefore, M1 may signal through 
an interaction with a nonclassical MHC class Ib molecule, or 
perhaps mediate some novel manipulation of TCR and CD8 
ligation that is entirely MHC independent. Further study of 
the molecular interactions involved in M1-mediated TCR 
activation will shed light on such possibilities. 
  V    4  +   CD8  +   T cell  –  mediated control of infection 
  M1-mediated stimulation of V    4  +   CD8  +   T cells promotes 
their continual proliferation, potent eff  ector cytokine pro-
duction, and long-term capacity to suppress viral reactivation 
apparently through IFN     production. These fi  ndings support 
a less appreciated role for noncytolytic CD8  +   T cell function 
mediated by eff  ector cytokines. The mechanism by which 
IFN     controls reactivation is not fully characterized, but even 
short-course IFN     blockade in vivo results in a greatly in-
creased frequency of MHV68 reactivation from PECs after 
explant (  7  ). Likewise, the increased frequency of PECs that 
reactivate in culture after an M1-null virus infection is likely 
the result of the relatively poor IFN     response elicited in the 
absence of V    4  +   CD8  +   T cell expansion. Obviously, the po-
tential sources of IFN     during infection are not limited to 
V    4  +   CD8  +   T cells. Indeed, the frequency of reactivation in 
the absence of M1 is less exaggerated than that of WT virus 
in mice lacking IFN     or its receptor (  59  ). CD4  +   T cells regu-
late MHV68 infection in an IFN    -dependent manner, 
whereas NK cells, although likely candidates, do not appear 
to regulate MHV68 infection (  60  –  62  ). 
  Stimulation by M1 does not appear to promote anti-
MHV68 cytolytic activity from V    4  +   CD8  +   T cells in vivo, 
because the frequency of latently infected cells does not de-
crease in their presence. Blackman et al. reported that V    4  +   
CD8  +   T cells kill targeted cells in a peptide-nonspecifi  c manner, 680 MHV68 M1 ANTIGEN INDUCES V   4 +   CD8 +   T CELLS | Evans et al.
that occurs via M1 stimulation. We propose that V    4  +   CD8  +   
T cells might exhibit aberrant cytolytic activity and bystander 
killing precisely because reactivating cells fail to respond to 
IFN    , as diagramed in   Fig. 7  . Elucidating a role for M1 in 
T cell activation will aid further attempts to understand the 
dynamic at work in this process. 
  Is there any evidence for superantigen function during 
human gammaherpesvirus infection or disease? EBV infec-
tion induces expression of a human endogenous retroviral 
superantigen (HERV-K18) encoded by the host cell (  69  ). 
The signifi   cance of such superantigen activation on EBV 
pathogenesis is unclear (  70, 71  ). T cell activation after EBV 
infection is signifi  cantly altered during IM, particularly in pa-
tients with a genetic defi  ciency of the lymphocyte signaling 
regulator SLAM-associated protein (SAP or   SH2D1A  ) (  72  ). 
These individuals develop a fatal syndrome known as X-
linked lymphoproliferative disease, presumably as a result of 
failure to properly regulate antiviral immune responses. This 
syndrome has been modeled using chronic viral infection of 
SAP-defi  cient mice (  73  ). Because the V    4  +   CD8  +   T cell re-
sponse has been proposed as a model for IM, it should be 
noted that the extent of V    4  +   proliferation after MHV68 
infection of SAP-defi  cient mice is immensely exaggerated 
(80  –  90% of all CD8  +   T cells in circulation are V    4  +   in some 
animals), and like their human counterparts, these mice de-
velop an immune-mediated pathology in multiple organs 
(  74, 75  ). This raises the question of whether, in both human 
and murine gammaherpesvirus infection, superantigen-like 
activity is involved in promoting infl  ammatory disease. Fur-
ther studies of these and other pathologies may identify new 
roles for microbial immunomodulatory molecules in pre-
sumptively autoimmune or chronic infl  ammatory processes. 
    MATERIALS AND METHODS   
  Viruses and tissue culture.     Viral stocks were generated by transfecting 
WT and mutant MHV68, cloned as a bacterial artifi  cial chromosome (BAC), 
into Vero-Cre cells to excise BAC sequence by Cre-mediated recombina-
tion (  76, 77  ). NIH 3T12 cells and mouse embryonic fi  broblasts (MEFs) were 
maintained in Dulbecco  ’  s modifi  ed Eagle  ’  s medium, supplemented with 
10% FCS, 100 U of penicillin per ml, 100 mg of streptomycin per ml, 
and 2 mM   l-  glutamine (CMEM). MEFs were obtained from C57BL/6 
mouse embryos as previously described (  78  ). Vero-Cre cells were a gift from 
D. Leib (Washington University, St. Louis, MO), and they were passaged in 
CMEM supplemented with 300 1   μ  g/ml g/ml Hygromycin B. 
  Mice and infections.    C57BL/6, BALB/c, and IFN   R      /      mice (B6.129S7-
  Ifngr  tm1Agt    /J) were purchased from The Jackson Laboratory and bred in Em-
ory University  ’  s animal facilities. Intranasal and intraperitoneal inoculations 
were performed in a total volume of 20   μ  l and 400   μ  l, respectively, diluted 
in CMEM accordingly. Mice were used between 8  –  14 wk of age and placed 
under isofl  urane anesthesia before infection and sacrifi  ce by cervical disloca-
tion. All protocols for animal studies were approved by the Institutional Ani-
mal Use and Care Committee of Emory University. 
  Histopathology and immunohistochemical slide preparation.     Organs 
were harvested and fi  xed overnight in 10% buff  ered formalin. 7-  μ  m sections from 
paraffi   n-embedded tissues were cut and stained with hematoxylin and eosin by 
the Veterinary Pathology offi   ce at Emory University. Images were acquired with 
an AXIO Imager.A1 microscope and an Axiocam MRc5 (Carl Zeiss, Inc.). 
critically important for V    4  +   CD8  +   T cell activation (  30, 
36  –  38, 64, 65  ). The strict requirement for M1 expression and 
B cell latency in the V    4  +   CD8  +   T cell response could be 
explained by several scenarios. The M1 ORF may be diff  er-
entially regulated by alternative promoter usage during B cell 
infection, similar to the manner in which EBV modulates 
diff  erent latent transcriptional programs (  66  ). Alternatively, 
naive V    4  +   CD8  +   T cells may require M1-expressing cells to 
reside within a specifi  c microenvironment or lymphoid tissue 
during primary stimulation, as is true for antigen-bearing cells 
during conventional T cell stimulation. Migration of infected 
B cells might be required in this latter scenario. Regardless, 
M1 provides a unique T cell  –  dependent mechanism to elicit 
host cytokine expression and subsequently inhibit virus reac-
tivation from non-B cell reservoirs that may be less amenable 
to long term maintenance of the latent viral genome. 
  In addition, such an extraordinary T cell response could 
explain several interesting immunological features of MHV68 
latency, such as why: (a) B cell  –  defi  cient mice fail to regulate 
persistent reactivation, but when reconstituted with B cells 
that do not recognize viral antigen control is recovered in a 
T cell  –  dependent manner (  64, 67  ); (b) CD8  +   T cells are ca-
pable of controlling virus reactivation even in the absence of 
classical MHC class Ia molecules (  41  ); (c) MHV68 infection 
results in enhanced lymphoproliferative disease in the absence 
of M1 in some settings (  68  ); and (d) M1 is required for 
MHV68 to promote CD8  +   T cell  –  mediated transplant rejec-
tion in latently infected recipients (unpublished data). The 
possibility that the V    4  +   CD8  +   T cell population is playing a 
role in each of these phenomena is consistent with the avail-
able data, and we suggest that this long underappreciated T 
cell response could aff  ect several of these interesting features 
of MHV68 latency. 
  Herpesviruses and immune dysfunction 
  MHV68-associated fi   brosis and vasculitis are proposed as 
models of several poorly understood clinical pathologies, im-
plicating latent or unknown herpesviruses in the pathogenesis 
of human disease. Although these MHV68-induced pathol-
ogies do not have perfect clinical correlates to known human 
gammaherpesvirus-associated diseases, they do provide proof 
that dysregulated immune function during persistent infec-
tion can produce devastating disease, the type that could be 
misinterpreted as purely autoimmune or idiopathic phenom-
enon if infection goes undetected. Fibrosis associated with 
MHV68 requires persistent viral replication (  11, 15  ), but we 
show that persistence is insuffi   cient in the absence of M1 ex-
pression and an activated V    4  +   CD8  +   T cell response. The 
relationship between persistent infection, T cells, and other 
cell types implicated in MHV68-induced fi  brosis (such as 
macrophages) presents a complex dynamic that will require 
careful dissection (  10  ). Pathological changes in V    4  +   CD8  +   
T cell activity could result from their own lack of IFN     
responsiveness. Alternatively, the chronic infl  ammatory envi-
ronment in persistently infected IFN    R      /      mice may enhance 
V    4  +   CD8  +   T cell activation, above and beyond the   “  priming  ”   JEM VOL. 205, March 17, 2008 
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  Generating recombinant M1.STOP virus.     WT MHV68 BAC DNA 
was mutagenized by allelic exchange in Rec-A  –  positive   Escherichia coli  , as 
previously described (  76  ), with the following modifi  cations. A DNA frag-
ment containing an M1 kanamycin insertion (M1.Kan) was generated by in-
corporating a novel Avr II restriction site into position 2153 (GenBank 
accession no.   NC_001826  ) of the M1 ORF with overlap extension PCR. 
The kanamycin resistance cassette from the Xbal fragment of pCP15 into 
this site was then subcloned into the AvrII site. The resulting M1.Kan con-
struct was transfered into the pGS284 suicide vector and allelic exchange was 
performed with the WT MHV68 BAC to generate a kanamycin-resistant 
BAC in which antibiotic resistance was linked to the M1 ORF (M1.Kan 
BAC). The M1.STOP mutation, as shown in   Fig. 2 C  , was also cloned by 
overlap extension PCR, incorporating two translational termination codons, 
a single base pair downstream frameshift, and a novel Acl I site into coordi-
nates 2363 through 2373. After sequence confi  rmation, the M1.STOP allele 
was cloned into pGS284, allowing allelic exchange to be performed with 
M1.Kan BAC to exchange the discrete stop mutation for the Kan insertion. 
M1.STOP BAC was identifi  ed by replica plating for the loss of kanamycin 
resistance, and the entire region was sequenced to confi  rm fi  delity. Genomic 
integrity of all recombinant BACs was confi  rmed by Southern blot (Fig. S5, 
available at http://www.jem.org/cgi/content/full/jem.20071135/DC1). 
M1.STOP viral stocks were generated as described. 
  Protein expression and detection.     M1 coding sequence (genomic co-
ordinates 2023  –  3285) was PCR amplifi  ed from MHV68 BAC DNA, incor-
porating a BamHI restriction site and a Kozac sequence immediately upstream 
of the translational start site and a XhoI restriction site immediately downstream 
of the last codon. Primer sequences were the following: 5    -TCGAACG-
GATCCGCCGCCATGCAGCTGGCCACCTTATG-3     and 5    -GGTT-
GCCTCGAGGGACTGCTGCCCAGGAAAAAT-3    . PCR products were 
cloned in-frame with the C-terminal FLAG epitope using the BamHI and 
XhoI sites contained in the pCMV-Tag4B mammalian expression vector 
(Stratagene) and sequenced for fi  delity. The M3 expression vector was 
generated in an identical manner, using primer sequences that correspond to 
genomic coordinates 6060  –  7277. The v-cyclin expression vector was generated 
by cloning sequence corresponding to genomic coordinates 102,423  –  103,181 
into pCMV-Tag2B (Stratagene). 
  Expression vectors were transfected into Cos-1 cells using TransIT-LT1 
Reagent (Mirus), per the manufacturer  ’  s instructions. After 48 h, transfected 
cell supernatants were removed and immunoprecipitated overnight using 
30   μ  l anti-FLAG M2-agarose affi   nity gel (Sigma-Aldrich). Whole-cell lysates 
were prepared by the addition of E1A lysis buff  er (50 mM Hepes, pH 7.2, 
250 mM NaCl, 2 mM EDTA, and 0.1% NP-40). Cell lysates and immuno-
precipitates were denatured and separated by 10% SDS-PAGE and trans-
ferred to nitrocellulose membrane. Nitrocellulose was blocked for 1 h at room 
temperature, immunoblotted overnight at 4  °  C with anti-FLAG M2-peroxidase  –
  conjugated antibody (Sigma-Aldrich), and antibody was detected using ECL 
Western Blot Analysis System (GE Healthcare). 
  Hybridoma stimulation.     V    4  +   CD8  +   hybridomas (4BH62 and 4BH98) 
were gifts from M. Blackman (Trudeau Institute, Saranac lake, NY), and the 
polyoma-specifi  c V    4-CD8  +   T cell hybridoma (LT359) was supplied by A. 
Lukacher (Emory University, Atlanta, GA). Notably, each line was gener-
ated from the fusion of mouse splenocytes with the same hybridoma fusion 
partner, BWZ.36/CD8     (  37  ). V    4  +   lines were maintained in Eagle  ’  s mini-
mum essential media supplemented with 8.5% FCS and 7.25% tumor cock-
tail (Eagle  ’  s minimum essential media with 75 ml of 10  ×   essential aa, 140 ml 
of 100  ×   nonessential aa, 100 mM sodium pyruvate, 2 mM   l-  glutamine, and 
7.5 g dextrose/liter, and then pH adjusted to 7.0 with sodium hydroxide be-
fore addition of 8.5 g sodium bicarbonate, 500 mg gentamycin, 600 mg 
penicillin, 1 g streptomycin, and 34   μ  l of 2-    -mercaptoethanol [    ME] per 
liter). LT359 was maintained in CMEM supplemented with sodium pyru-
vate, nonessential aa, and     ME at the same concentrations indicated in the 
aforementioned tumor cocktail. During stimulation, 10  5   hybridoma cells 
were cultured for 24  –  36 h in fl  at-bottom, 96-well plates, in the presence of 
  Immunohistochemistry was performed on fresh frozen lung sections. 
Mounted serial sections were blocked before staining for V    4 TCR and 
CD8     (both rat anti  –  mouse; AbD Serotec) or normal rat IgG (Santa Cruz 
Biotechnology) as a negative control. Secondary biotinylated rabbit anti  –  rat 
(Dako) was used before quenching endogenous peroxidase activity with 
0.3% H  2  O  2   and exposure to a streptavidin/horseradish peroxidase conjugate 
and diaminobenzidine (Vector Laboratories) as chromogen. 
  Flow cytometry and intracellular cytokine staining.     Single-cell sus-
pensions resuspended in PBS with 1  –  2% FCS (FACS Buff  er). For staining, 
1  –  2   ×   10  6   cells were Fc-blocked with 1:50 dilution of anti-Fc    II/IIIR 
(2.4G2) before staining with each of the following monoclonal antibodies: 
V    4 TCR (KT4), CD11a (M17/4), CD44 (IM7), CD62L (MEL-14), 
CD25 (7D4), CD69 (H1.2F3), CD127 (SB/199), PD-1 (J43), NKG2A 
(16A11; BD Biosciences), and CD8     (CT-CD8a; Caltag Laboratories). 
Various fl  uorophore conjugates for each monoclonal species were used in 
diff  erent panels depending on the availability of each conjugated activation 
marker. For BrdU analysis, mice were given fresh BrdU daily in their drink-
ing water (0.8 mg/ml) for 8 d starting 4 mo after infection. Intracellular 
staining used a BrdU fl  ow kit (BD Biosciences) and followed the manufac-
turer  ’  s instructions. Stimulation of cytokine production entailed culturing 
splenocytes for 4  –  6 h in the presence of a 1:100  –  1:1,000 dilution of 
GolgiPlug (BD Biosciences) in fresh CMEM with or without the addition of 
either 1   μ  g/ml of anti-CD3 monoclonal (145-2C11; BD Biosciences). 
The stimulatory activity of each recombinant protein was assessed by the 
addition of GolgiPlug alone to the supernatant from Cos-1 cells 48 h after 
transfection, and then using the supernatant for splenocyte culture. After 
stimulation, surface staining was performed as above, followed by cell per-
meabilization and fi  xation (Cytofi  x/Cytoperm kit; BD Biosciences) and in-
tracellular staining for V   4 TCR (required because of surface downmodulation 
during stimulation), IFN     (XMG1.2), and TNF-    . Data were collected on 
a FACSCalibur (BD Biosciences) and analyzed using FlowJo software (Tree 
Star, Inc.). 
  Plaque assays.     Plaque assays were performed as previously described (  18  ), 
with the following alterations. Tissues were weighed before freezing in 
1 ml CMEM, and then thawed and homogenized by mechanical disrup-
tion with 1.0 mm zirconia/silica beads in a Mini-Beadbeater 8 (Biospec 
Products). 10-fold dilutions made in CMEM were plated onto monolayers 
of 2   ×   10  5   NIH 3T12 fi  broblasts. Samples were overlaid with 5 ml of 
2% methylcellulose in CMEM, and after 7 d, plaques were counted by 
microscopic examination. Plaque titers were normalized per gram of tissue, 
and the limit of detection for this assay is based on detection of 5 PFU 
per 0.1 g of tissue. 
  Limiting dilution ex vivo reactivation assay.     Detection of MHV68 re-
activation from latency was performed as previously described (  67  ). In brief, 
cells were plated in a series of twofold dilutions, starting at 10  5   cells per well, 
onto MEF monolayers in 96-well tissue culture plates. After 21 d, wells were 
scored microscopically for the presence of CPE. To detect preformed infec-
tious virus, parallel samples were subjected to mechanical disruption as previ-
ously described, killing   >  99% of cells. Disrupted cells were plated in a similar 
series of twofold dilutions. 
  Limiting dilution nested PCR detection of MHV68 genome-posi-
tive cells.     We determined the frequency of cells containing MHV68 
genome using a previously described nested PCR assay (LD-PCR) with 
approximately single-copy sensitivity to detect gene 50 of MHV68 (  67  ). 
In brief, cells were counted and resuspended in an isotonic solution, and 
diluted in a background of 10  4   uninfected NIH 3T12 cells. After overnight 
lysis of cells with proteinase K, two rounds of nested PCR were performed 
on each sample. Products were analyzed by ethidium bromide staining of a 
2% agarose gel. To quantitate PCR sensitivity, 10, 1, or 0.1 copies of a gene 
50 containing plasmid (p  Bam  H I N) were diluted into a background of 10  4   
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  2003  .   Murid herpesvirus 4 strain 68 M2 protein is a B-cell-associated 
Cos-1  –  conditioned supernatants. After stimulation, supernatants were re-
moved and analyzed for the presence of IL-2 by ELISA (BD Biosciences) 
according to the manufacturer  ’  s instructions. LacZ expression was detected 
by washing cells with PBS, fi  xing with cold 2% formaldehyde/0.2% glutar-
aldehyde for 5 min, washing again, and fi  nally staining with the addition of 
50   μ  l of PBS containing 5 mM potassium ferrocyanide, 5 mM potassium fer-
ricyanide, 2 mM MgCl  2  , and 1 mg/ml of 5-bromo-4-chloro-3-indolyl     -
D-galactopyranoside (X-Gal). Cells were incubated for an additional 6  –  12 h 
at 37  °   before being photographed with an inverted tissue culture microscope 
(Carl Zeiss, Inc.). 
  Antibody depletion.     The KT4 rat hybridoma cell line was a gift from 
G. Deepe (University of Cincinnati, Cincinnati, OH). The SFR-DR5, IgG2b 
isotype control  –  producing rat hybridoma was a gift of E. Barton (Purdue 
University, West Lafayette, IN). Both cell lines were grown in serum-free 
hybridoma media (Invitrogen) supplemented with 100 U of penicillin and 
100 mg of streptomycin per ml (SFM), using a two-compartment bioreactor 
(Integra Biosciences) to generate concentrated, serum-free, and cell-free 
antibody preparations. The relative concentration of each monoclonal species 
was measured by enzyme-linked immunosorbent assay (ELISA) for total rat 
IgG2b (Bethyl Laboratories). Each antibody was diluted to an equivalent 
concentration in SFM, and 300   μ  g was injected intraperitoneally into in-
fected mice every 3 d starting at 32 d after infection. Mice were killed 10 d 
later and the extent of V    4  +   T cell depletion was assessed independently by 
surface staining for V    4 TCR and IFN     production. 
  Statistical analysis.     All data were analyzed using GraphPad Prism software 
(GraphPad Software). Titer data were compared using an unpaired, two-
tailed Student  ’  s   t   test to evaluate statistical signifi  cance. Histograms denoting 
the percentage of V    4  +   CD8  +   T cells elicited by each virus in each respec-
tive mouse strain represent the mean value   ±   the SEM from 1  –  4 individual 
experiments with 2  –  5 mice per group. Limiting dilution analyses for the 
evaluation of latent infection represents pooled data from 2  –  3 individual ex-
periments containing 4  –  5 mice per group. Data were subjected to nonlinear 
regression analysis, and the frequency for reactivation or the detection of a 
genome-positive cell was found using the Poisson distribution to assume that 
the cell number at which 63.2% of events were detected corresponded to the 
occurrence of a single event. 
  Online supplemental material.     Fig. S1 shows the ICC staining results for 
M1-mediated IFN     production from WT, M1.STOP-infected, and naive 
mice. Fig. S2 outlines the attempted V    4-depletion regimen and shows the 
results for both V    4 and IFN     staining from KT4- versus isotype control-
treated mice. Fig. S3 shows the diagnostic Southern blot confi  rming the 
construction and overall genomic integrity of the M1.STOP BAC. Fig. S4 
shows the frequency of antigen-specifi  c (p56/H-2D  b  ) CD8  +   T cells elicited 
by M1.STOP versus WT virus. Fig. S5 shows that both the frequency of 
MHV68 reactivation and the extent of V    4  +   CD8  +   T cell expansion are in-
dependent of viral dose. The online version of this article is available at 
http://www.jem.org/cgi/content/full/jem.20071135/DC1. 
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